Abstract:Accumulating evidence has proposed a model that tumorigenesis is driven by cancer stem cells (CSCs). Those CSCs are capable of sustaining self-renewal, developing into phenotypically diverse cancer cell populations, proliferating extensively and being resistant to treatment. Toll-like receptor 9 (TLR9) has been described to trigger innate and adaptive immune responses that may promote an antitumor immune response against cancers. Our previous data show that activation of TLR9 by CpG-ODN could activate IKK/NF-kB, MAPK/AP-1 and PI3K/Akt signal pathways. We also demonstrated that increased expression of TLR9 results in promoted migration, invasion and metastasis in lung cancer cells. Thus, as a cancer progression associated factor, TLR9 might also be involved in stem-cell function in cancer. We separated CSCs from cell lines and lung cancer tissues by CSC marker CD133 and ALDH. Then we knock down the expression of TLR9 and then investigate biological changes of CSCs, including sphere formation, self-renewing ability, invasion, resistance to drugs, and in vivo tumor formation. We found toll-like receptor (TLR9) are constitutively overexpressed on cancer stem cells (CSCs) derived from lung cancer cell lines and patients’ tissue when compared with non-stem cells. Knocking down of TLR9 in lung CSCs resulted in inhibited capacity for proliferation, invasion, tumorigenesis and resistance to chemotherapeutic drugs. Furthermore, cell cycle was arrested at G2/M stages and more apoptosis existed after TLR9 expression decreased. Further analysis indicated that TLR9 maintain the stemness of cancer cells by changing expression of other stem cell markers Gli1, Notch1 and beta-catenin, drug transporters ABCB1, ABCC1 and ABCG2 and anti-apoptotic factors BCL2 and Survivin. Of which, beta-catenin, was found to be most obviously related with TLR9 expression. Moreover, TLR9 expression was positively associated with tumor differentiation and inversely associated with lung cancer patient survival in clinic. Based on above data, TLR9 is crucial for marker and phenotype of lung CSC. It might work as a lung cancer stem cell maintainer.

TLR4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma.

Toll-like Receptor 4 Signaling Promotes Invasion of Hepatocellular Carcinoma Cells Through MKK4/JNK Pathway.

TLR4 Signaling Promotes Immune Escape of Human Lung Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance.

Toll Like Receptor 4 Facilitates Invasion and Migration As A Cancer Stem Cell Marker in Hepatocellular Carcinoma

TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells.

Lipopolysaccharide-Induced Toll-Like Receptor 4 Signaling in Cancer Cells Promotes Cell Survival and Proliferation in Hepatocellular Carcinoma

Toll-like Receptor 4 Signaling Promotes Epithelial-Mesenchymal Transition in Human Hepatocellular Carcinoma Induced by Lipopolysaccharide

Inflammatory Factor Receptor Toll‐like Receptor 4 Controls Telomeres Through Heterochromatin Protein 1 Isoforms in Liver Cancer Stem Cell

Toll-like Receptor-4 is a Target for Suppression of Proliferation and Chemoresistance in HepG2 Hepatoblastoma Cells.

TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC

The Role of Toll-Like Receptors (tlrs) in Pan-Cancer

Toll-like Receptor 4 and Its Associated Proteins As Prognostic Factors for HCC Treated by Post-Radiotherapy Surgery.

Toll-Like Receptor 4 Prompts Human Breast Cancer Cells Invasiveness via Lipopolysaccharide Stimulation and Is Overexpressed in Patients with Lymph Node Metastasis

Emerging Role of Toll-like Receptor 4 in Hepatocellular Carcinoma

Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A

PUB051 TLR9 is Functional Marker for Cancer Stem Cell in Non-Small Cell Lung Cancer

The effects of TLR4 activation on the characterizations of hepatocellular carcinoma cell line H7402

TLR4 Promotes Breast Cancer Metastasis Via Akt/GSK3β/β-Catenin Pathway Upon LPS Stimulation.

TLR4 Signaling Promotes Immune Escape of Human Colon Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance

Hepatocellular Carcinoma and Macrophage Interaction Induced Tumor Immunosuppression Via Treg Requires TLR4 Signaling.

Lipopolysaccharide Supports Maintaining the Stemness of CD133(+) Hepatoma Cells Through Activation of the NF-κB/HIF-1α Pathway.